Pembrolizumab plus dual HER2 blockade may offer a chemo-free option for early HER2+ breast cancer, phase 2 data suggest. Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy. A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication. Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer. Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer. Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions. Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer. Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade. Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy. Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends. A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer. Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive. The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results. The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4 TILs can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who can reduce adjuvant therapy. Aliya Omer, AstraZeneca, talks about data that backs the efficacy of olaparib in treating high-risk early breast cancer. In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death. The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease. New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.